Centogene N.V. announced it has extended its partnership with Takeda to diagnose patients with rare metabolic and rare neurodegenerative diseases. Under the agreement, CENTOGENE will continue providing Takeda access to diagnostic testing for patients around the world. The commercial fee-for-service agreement focuses on expanding patient access to diagnostics for lysosomal storage disorders such as Fabry and Gaucher diseases, and Hunter syndrome Within the partnership, CENTOGENE's proprietary CentoCard(R) dried blood spot solution provides easy logistics for central diagnostic testing.

A key asset to the partnership is the CENTOGENE Biodatabank which is pioneering access to commercial multiomic products on the market today. In January 2015, CENTOGENE originally entered into an agreement with Shire Pharmaceuticals, which was acquired in 2019 by Takeda, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from genetic rare diseases. Last year, the contract was extended until March 2022.